AbbVie Inc. (ABBV) - Stock Analysis
Last updated: Jun 6, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
AbbVie beat Q2 2025 earnings with raised full-year guidance based on strong sales of key drugs, pipeline advancements, and a 6% dividend increase. The ~6% recent price rise and moderate upward technical momentum, despite nearing resistance, point to moderate near-term capital appreciation potential.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong cash conversion ⢠Negative equity ⢠High leverage AbbVie generates strong margins and cash flow, but its leveraged, negative-equity balance sheet and rich valuation make the stock dependent on continued execution.
Price Behavior
Key Price Behavior Insights: ⢠Breakout Confirmed ⢠Support Holding ⢠Overbought Risk Support Level: $210-$211 Resistance Level: Recent highs Over the last month, ABBV has broken out to new short-term highs and remains constructive as long as it holds the low- to mid-$210s, though the sharp run-up leaves it stretched and prone to a pause or pullback.
Sentiment & News
Key News Insights: ⢠Skyrizi Momentum ⢠Raised Guidance ⢠Oncology Pressure AbbVie's mid-May results showed strong revenue and raised EPS guidance, driven by Skyrizi/Rinvoq growth that is offsetting Humira declines despite some oncology and competitive pressure.
AI Summary
AbbVie's improved growth durability from Skyrizi, Rinvoq, and neuroscience plus strong free cash flow makes the earnings upgrade credible, but with the stock already pricing in much of that success, elevated leverage and franchise concentration mean it looks better to hold than chase here.
Description
AbbVie Inc. is a global pharmaceutical company that discovers, develops, manufactures and markets prescription drugs across immunology, oncology, neuroscience, virology and eye care. Its portfolio includes established biologics and small-molecule therapies for conditions such as autoimmune diseases, cancer, hepatitis C, Parkinsonâs and glaucoma, alongside specialty products for endocrine and gastrointestinal disorders. The company was incorporated in 2012, is headquartered in North Chicago, Illinois, and maintains external research collaborations, including an agreement with Dragonfly Therapeutics.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 29 | Oct 6 | ABBV | AbbVie Inc. | AbbVie beat Q2 2025 earnings with raised full-year guidance based on strong sales of key drugs, pipeline advancements, and a 6% dividend increase. The ~6% recent price rise and moderate upward technical momentum, despite nearing resistance, point to moderate near-term capital appreciation potential. | Closed | +3.1% |